Urges U.S. Department of Health and Human Services and federal Centers for Medicare and Medicaid Services to reconsider implementation of new rules concerning organ procurement organizations.
Assembly Resolution 143 is a nonbinding legislative resolution that urges the U.S. Department of Health and Human Services and the Centers for Medicare and Medicaid Services (CMS) to reconsider federal rules governing organ procurement organizations (OPOs). The resolution focuses on CMS’s revised outcome measures and the new process for decertifying OPOs and requiring competitive bidding for designated service areas. It argues that these changes could disrupt the existing organ donation and transplantation network, create uncertainty for OPOs, and reduce the number of organs procured and transplanted.
The resolution frames organ donation as a critical public health function and emphasizes the scale of the transplant waiting list, the limited number of potential donors, and persistent racial disparities in transplant access. It contends that the current OPO system is already a national “gold standard” and that the federal rule may impose unnecessary instability rather than improving performance. The measure does not change New Jersey law directly; instead, it expresses the General Assembly’s position and directs that copies be sent to federal officials.
The bill’s practical impact is limited to advocacy and political pressure at the federal level. If adopted, it would not regulate OPOs in New Jersey or alter state statutes, but it would formally register the Assembly’s opposition to the CMS rule and support reconsideration of implementation. The resolution is aimed at federal agencies and is intended to influence how national organ procurement standards are applied.
The general sentiment reflected in the text is strongly opposed to the CMS rule and supportive of maintaining stability in the organ procurement system. The resolution presents the rule as potentially disruptive and harmful to transplant access, especially for racial and ethnic minority patients who already face disparities. No committee testimony or vote record is provided, so there is no additional evidence of internal legislative debate or bipartisan support/opposition beyond the resolution’s stated position.
The main point of contention is whether federal competition and decertification requirements would improve organ procurement performance or instead undermine an effective system. Supporters of reconsideration argue that lower-performing OPOs should receive guidance and support rather than decertification, and that local and regional differences are not adequately accounted for in the rule. The opposing view, implied by the federal rule itself, is that new performance measures and competition could increase donation and transplantation rates.
AR143 does not amend New Jersey statutes or impose state-level regulatory requirements; it is a concurrent-style policy resolution that communicates the Assembly’s opposition to a federal CMS rule. Its effect is to urge federal reconsideration of revised organ procurement organization outcome measures, decertification procedures, and competitive bidding requirements, and to transmit that position to HHS and CMS. The resolution is aimed at influencing federal policy affecting organ procurement organizations, transplant waiting lists, and related stakeholders such as donors, families, hospitals, and patients, particularly those in underserved communities.
The sentiment around the bill is strongly supportive within the resolution’s text and strongly critical of the federal CMS rule it addresses. The measure portrays the existing organ procurement system as effective and warns that the new rule could create instability, reduce organ recovery and transplantation, and worsen disparities for racial and ethnic minority patients. No vote history or committee transcript is available, so the broader legislative sentiment cannot be measured from recorded debate, but the introduced resolution clearly reflects opposition to the federal changes.
The central contention is whether CMS’s new OPO rules would improve accountability and donation rates or instead disrupt a functioning national transplant network. Critics in the resolution argue that decertification and competitive bidding could weaken service continuity, burden OPOs with larger service areas, and fail to account for regional differences and inequities in access to care. The resolution also highlights concern that the rule could disproportionately harm minority patients who already experience lower transplant rates. The countervailing position, reflected in the federal rule being challenged, is that transparent performance metrics and competition are needed to raise donation and transplantation outcomes.